BMS and bluebird Bio's competing BCMA cell therapy Abecma (idecabtagene vicleucel or ide-cel) was approved by the FDA in March, and was also filed for approval with the EMA, initially with ...

Why have BMS investors been anything but positive about acquiring 2seventy? The answer stems from uncertainty over how ...

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...

of the European Medicines Agency (EMA) recommending marketing authorization of Selincro (nalmefene) for the reduction of alcohol consumption in adult patients with alcohol dependence who have a ...

As diplomatic tensions continue between Canada and the United States, a travel group says Islanders are rethinking their travel plans, opting for alternative vacation destinations that are either ...

The harmful use of animals in experiments is not only cruel but also often ineffective. Animals do not naturally get many of the diseases that humans do, such as major types of heart disease, many ...

Chinese authorities issued guidelines on Friday requiring labels on all artificial intelligence-generated content circulated online, aiming to combat the misuse of AI and the spread of false ...

Help us protect the clean athlete and the integrity of sport. Every time someone steps forward with information on doping, we move closer to a clean and fair playing field for all. Report Doping This ...

19 March 2025 UK biotech Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology (I-O) and antibody drug conjugate (ADC)-based therapies, today announced a ...